机构地区:[1]河南中医药大学药学院,河南郑州450046 [2]河南中医药大学第一附属医院药学部,河南省中药临床应用、评价与转化工程研究中心,河南省中药临床药学中医药重点实验室,河南郑州450000 [3]中国人民解放军总医院第五医学中心,北京100039
出 处:《中草药》2024年第8期2630-2640,共11页Chinese Traditional and Herbal Drugs
基 金:河南省高校科技创新团队(23IRTSTHN026);国家自然科学基金面上项目(82173993);国家中医管理局中医药高质量发展协同创新转化工程自主立项项目(CXZH03)。
摘 要:目的以抗炎为例,建立基于效应成分指数(effect-constituents index,ECI)的金银花配方颗粒质量一致性评价方法。方法采用超高效液相色谱法测定22批次不同标准(国标/企标)的金银花配方颗粒样品中9种具有抗炎活性的单体成分(新绿原酸、绿原酸、隐绿原酸、断马钱子酸、断氧化马钱子苷、木犀草苷、异绿原酸B、异绿原酸A、异绿原酸C)含量,采用环氧合酶-2(cyclooxygenase-2,COX-2)试剂盒测定上述样品的抗炎效价和相关单体成分的半数抑制浓度(half inhibitory concentration,IC_(50)),进而整合分析获取上述各个成分的抗炎效价权重系数,通过权重系数和效价整合计算得到ECI,最后通过细胞实验验证所构建的ECI的可行性。结果抗炎成分含量测定结果显示,9种单体成分含量存在较大的差异,其中国标批次(S1~S11)和企标批次(S12~S22)在单体成分的含量高低也存在显著差异,如国标批次(S8)中绿原酸的含量是企标批次(S16)中该成分含量的3.3倍(43.06 vs 12.98 mg/g)。国标(S1~S11)样品的整体稳定性与企标(S12~S22)样品相差不大(RSD_(国标)=211.55,RSD_(企标)=215.71)。生物效价测定方法通过了方法学考察,结果显示国标样品的抗炎效价和稳定性比企标更好(效价_(国标)=100.28~106.35 U/m L,效价_(企标)=88.06~95.49 U/m L;RSD_(国标)=1.98,RSD_(企标)=2.56)。ECI理论计算结果显示该方法结果与实验结果一致,能够反映金银花配方颗粒样品的药效关系(ECI_(国标)=10.82~14.11,ECI_(企标)=9.32~12.58;RSD_(国标)=9.51,RSD_(企标)=10.02)。相关性分析显示单一指标性成分的含量与抗炎效价之间正相关性较好的是绿原酸(r=0.644),其次是木犀草苷(r=0.581),说明这2个成分在抗炎活性中起主要作用。结论以抗炎为例,建立基于效应成分指数的金银花配方颗粒质量评价方法。可应用于多批次不同标准(国标/企标)的金银花配方颗粒的质量一致性评价,为其他具有类Objective To establish a method for quality consistency evaluation of Jinyinhua(Lonicerae Japonicae Flos)dispensing granules based on effect-constituents index(ECI)by taking anti-inflammation as an example.Methods Ultra performance liquid chromatography(UPLC)was used to determine the contents of nine monomer components(neochlorogenic acid,chlorogenic acid,cryptochlorogenic acid,secologanic acid,secoxyloganin,cymaroside,isochlorogenic acid B,isochlorogenic acid A,isochlorogenic acid C)with anti-inflammatory activity in 22 batches of Lonicerae Japonicae Flos dispensing granules of different standards(national standard/enterprise standard,NS/ES),and the anti-inflammatory potency of the above samples and half inhibitory concentration(IC_(50))of the relevant monomer components were determined by using the cyclooxygenase-2(COX-2)kit,and then the weight coefficient of anti-inflammatory potency of the above components was obtained by integrative analysis,and ECI was calculated through the integration of weight coefficients and effectors,and finally,the feasibility of the constructed ECI was verified by cellular experiments.Results The results of anti-inflammatory component content determination showed that there were large differences in the contents of nine individual components,of which there were also significant differences in the content of individual components between the NS batch(S1—S11)and the ES batch(S12—S22),for example,the content of chlorogenic acid in the NS batch(S8)was 3.3 times more than the content of this component in the ES batch(S16)(43.06 vs 12.98 mg/g).The overall stability of NS(S1—S11)samples was not much different from that of ES(S12—S22)samples(RSDNS=211.55,RSDES=215.71).The bioefficacy assay passed the methodological examination,and the results showed that the anti-inflammatory potency and stability of the NS samples were better than those of the ES samples(potency_(NS)=100.28—106.35 U/mL,potency_(ES)=88.06—95.49 U/mL;RSD_(NS)=1.98,RSD_(ES)=2.56).The theoretical calculations of EC
关 键 词:质量评价 效应成分指数 抗炎 金银花 配方颗粒 新绿原酸 绿原酸 隐绿原酸 断马钱子酸 断氧化马钱子苷 木犀草苷 异绿原酸B 异绿原酸A 异绿原酸C
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...